In the latest episode of PharmTech‘s Behind the Headlines, Autolomous CEO, Alexander Seyf, joined a panel of experts to dissect the commercial growing pains of the cell and gene therapy (CGT) sector. Panellists explored the urgent need for structural integration and the lessons we can learn from emerging academic manufacturing models.

Key highlights from the discussion include:
👉 Current CGT manufacturing is hindered by fragmentation and redundancy, with duplicated facilities and disjointed digital workflows creating significant scalability barriers.
👉 External economic pressures, including rising energy costs and shifting tariffs, are adding further strain to an already high-cost manufacturing environment.
👉 Successful scaling requires a shift toward harmonized systems and shared infrastructure to move away from the inefficiencies of the current decentralized landscape.

Watch the full panel here.